Work

Supplementary Figures S1-S2 from Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of TH-302, a Hypoxia-Activated Prodrug, in Patients with Advanced Solid Malignancies

Year: 2023

Type: supplementary-materials

Abstract: Supplementary Figures S1-S2.

DOI: 10.1158/1078-0432.22442993

Authors: Glen J. Weiss, Jeffrey R. Infante, E. Gabriela Chiorean, Mitesh J. Borad, Johanna C. Bendell, Julian R. Molina, Raoul Tibes, Ramesh K. Ramanathan, Karen Lewandowski, Suzanne F. Jones, Mario E. Lacouture, Virginia K. Langmuir, Hank Lee, Stew Kroll, Howard A. Burris

Language: English

Topic: Cancer, Hypoxia, and Metabolism

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361880656

Cites:

Cited by:

Related to: 10